AI Meets Ingredient Innovation

As the nutraceutical industry continues to push toward faster, more science-driven innovation, companies are increasingly looking to artificial intelligence to streamline traditionally fragmented workflows.

Recent developments from Brightseed, including the launch of its enterprise AI-powered Innovation Platform,^1,2 highlight a shift toward integrating ingredient discovery, validation, and commercialization within a single ecosystem.

The platform builds on Brightseed’s Forager AI engine and expansive database of natural compounds to help identify bioactives and connect them with relevant health outcomes and supporting evidence. In this Q&A, Lee Chae, PhD, Brightseed’s CEO, describes how this approach could help supplement and functional food companies reduce development timelines, strengthen claims substantiation, and improve the likelihood of commercial success.

Nicholas Saraceno: For dietary supplement and functional food companies, ingredient discovery, clinical substantiation, and commercialization are often handled by multiple external partners, which can slow development timelines. How does the Brightseed Innovation Platform change the way companies move from ingredient discovery to validated, commercial-ready products within a more unified workflow?

Lee Chae: Brightseed accelerates bioactive ingredient discovery and validation by combining its proprietary natural compound dataset with AI models that predict bioactivity across major health areas, specific benefits, and relevant biological targets.

It then links those predictions to structured evidence, including dosage, study context, regulatory status, and history of human consumption, so teams can quickly prioritize ingredients with stronger validation potential and better formulation fit.

The workflow reduces the time and uncertainty involved in identifying formulation-ready nutraceutical ingredients.

Saraceno: Structure-function claims and health benefit substantiation remain major hurdles for supplement companies. How can companies use the Brightseed platform and its biological data to better support claims and scientific positioning for new ingredients?

Chae: The platform captures structured data from supporting studies, including bioactive dosage range, human equivalent dose where preclinical data exists, treatment duration, and species. This helps users assess whether an efficacy signal is supported by human evidence or relies on animal-to-human extrapolation.

Regulatory status is also surfaced within the workflow, giving users clearer visibility into the compliance profile of compounds as dietary supplement ingredients. In addition, the platform tracks history of human consumption and compound material format, such as pure compound versus extract, providing further context for safety assessment, formulation decisions, and regulatory acceptability.

Saraceno: What are the most common reasons early product ideas fail, and how can those risks be reduced earlier in development?

Chae: Promising bioactives tend to fail for a few common reasons: early results do not translate in humans; the effective dose or bioavailability is not practical; the ingredient cannot be standardized consistently; or the safety, regulatory, intellectual property, and claims support is not strong enough for commercialization.

AI helps reduce that risk by identifying stronger candidates earlier, connecting biological predictions with supporting evidence and real-world product constraints, and helping teams focus validation efforts on ingredients with a clear path to market. Over time, this creates a flywheel effect. Each round of prediction, validation, and evidence generation improves the system, making future discovery faster, more targeted, and more commercially informed.

Saraceno: Forager, the AI engine at the core of the platform, has already identified phytonutrients that are now in commercial products. How might supplement brands or ingredient suppliers interact with Forager to identify new bioactives or new health benefit applications for existing ingredients?

Chae: We have identified over 13 million compounds across 23 health territories and use this to accelerate bioactive ingredient discovery and validation by combining its proprietary natural compound dataset with AI models that predict bioactivity across major health areas, specific benefits, and relevant biological targets.

It then links those predictions to structured evidence, including dosage, study context, regulatory status, and history of human consumption, so teams can quickly prioritize ingredients with stronger validation potential and better formulation fit.

References

1. Brightseed launches the world’s first clinically-validated, enterprise AI platform, built on over a decade of scientific research. Brightseed. Published March 25, 2026. Accessed April 8, 2026. https://www.brightseedbio.com/wp-content/uploads/2026/03/brightseed-platform-announcement-03252026-1.pdf

2. Brightseed official website. Brightseed. Accessed April 8, 2026. https://www.brightseedbio.com/